65 reports

  • Gastrointestinal Drugs Market Forecast Growth
  • Gastrointestinal Drugs Market Historic Growth
  • Gastrointestinal Drug
  • World
  • Allergan plc
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited
  • GASTROINTESTINAL THERAPEUTICS MARKET, GLOBAL, APPROVED GASTROINTESTINAL
  • GASTROINTESTINAL THERAPEUTICS MARKET, GLOBAL, APPROVED GASTROINTESTINAL
  • Gastrointestinal Drug
  • World
  • Market Size
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited
  • Zantac
  • GLOBAL GERD DRUGS MARKET BY GEOGRAPHY 2015

Offers a wide range of drugs and pharmaceuticals for the treatment of neuroscience and gastrointestinal diseases.

  • Gastrointestinal Drug
  • World
  • AstraZeneca PLC
  • Eisai Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • 07. Epidemiology of Gastrointestinal Disorders
  • GLOBAL GASTROINTESTINAL OTC DRUGS MARKET BY THERAPEUTIC CLASS OF DRUG
  • Gastrointestinal Drug
  • World
  • GlaxoSmithKline plc
  • Perrigo Company
  • Pfizer Inc.

The market is further broken down into the drugs to treat specific disorders within the gastrointestinal system, including the following: - Gastrointestinal tract disorders. - Gastrointestinal tract walls disorders. - Gastrointestinal motility disorders. -

  • Gastrointestinal Drug
  • OTC
  • World

Global Gastrointestinal Drugs Market : IGR Snapshots ##. ## Global Gastrointestinal Drugs Market key trends ##. ## Global Gastrointestinal Drugs Market by drug category ##. ## Global Gastrointestinal Drugs Market by route of administration ##. ## Global

  • Gastrointestinal Drug
  • OTC
  • World
  • Market Size

For instance, Amitiza causes nausea, dyspnea, mechanical gastrointestinal obstruction, and diarrhea.

  • Gastrointestinal Drug
  • World
  • AstraZeneca PLC
  • Sucampo Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited

GERD is one of the commonly observed recurrent gastrointestinal disorders worldwide.

  • Gastrointestinal Drug
  • OTC
  • World
  • Market Size

Some of the prominent trends that the market is witnessing include occurrence of serious health issues with excessive usage of saline laxative, growing incidence of gastrointestinal diseases, recent technological developments of Saline Laxative and growth opportunities/ investment oppor

  • Gastrointestinal Drug
  • OTC
  • Europe
  • World
  • Forecast
  • Clinical Trials by E7 Countries: Proportion of Diarrhea to Gastrointestinal Clinical...
  • Proportion of Diarrhea to Gastrointestinal Clinical Trials, G7 Countries (%), 2015*
  • Drug Discovery And Development
  • Gastrointestinal Drug
  • World
  • Furiex Pharmaceuticals, Inc.
  • Sanofi S.A.
  • PROPORTION OF REFLUX ESOPHAGITIS (GASTROESOPHAGEAL REFLUX DISEASE) TO GASTROINTESTINAL...
  • PROPORTION OF REFLUX ESOPHAGITIS (GASTROESOPHAGEAL REFLUX DISEASE) TO GASTROINTESTINAL...
  • Gastrointestinal Drug
  • World
  • AstraZeneca PLC
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • ESOPHAGITIS THERAPEUTICS, GLOBAL, TERMINATED CLINICAL TRIALS, 2015*
  • ESOPHAGITIS THERAPEUTICS CLINICAL TRIALS MARKET, GLOBAL, CLINICAL TRIALS BY TAKEDA PHARMACEUTICAL...

Mechanism of Action Vonoprazan fumarate (Takecab) is a novel anti-secretory drug, acts as gastrointestinal Protective Agent, formulated as tablets for the oral route of administration.

  • Gastrointestinal Drug
  • World
  • AstraZeneca PLC
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • ESOPHAGEAL DISEASES THERAPEUTICS, GLOBAL, TERMINATED CLINICAL TRIALS, 2015*
  • ESOPHAGEAL DISEASES THERAPEUTICS CLINICAL TRIALS MARKET, GLOBAL, CLINICAL TRIALS BY TAKEDA...

Mechanism of Action Lafutidine (Protecadin, Stogar) is an anti-ulcer drug and a gastrointestinal agent.

  • Gastrointestinal Drug
  • World
  • AstraZeneca PLC
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, E7 Countries...
  • Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, G7 Countries...
  • Drug Discovery And Development
  • Gastrointestinal Drug
  • World
  • GlaxoSmithKline plc
  • Salix Pharmaceuticals, Ltd.

PROPORTION OF NONEROSIVE REFLUX DISEASE (NERD) TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2015* PROPORTION OF NONEROSIVE REFLUX DISEASE (NERD) TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2015* PROPORTION OF NONEROSIVE REFLUX DISEASE (NERD) TO

  • Gastrointestinal Drug
  • World
  • ALTANA AG
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited
  • DATA PARAMETERS AND DEFINITIONS (1)
  • UNHEALTHY LIFESTYLE TRENDS

The gut is especially vulnerable to tension and can demonstrate stress-induced physiological changes causing gastrointestinal discomfort.

  • Gastrointestinal Drug
  • World
  • Demand
  • Procter & Gamble Company
  • Sanofi S.A.
  • Clinical Trial profile. 398 Trial Title

ESOPHAGITIS THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY TRIAL STATUS, 2017* CLINICAL TRIALS BY E## COUNTRIES: PROPORTION OF ESOPHAGITIS TO GASTROINTESTINAL CLINICAL TRIALS AMONG THE E## (BRAZIL, RUSSIA, INDIA, CHINA, MEXICO, TURKEY AND INDONESIA) COUNTRIES, BRAZIL HAVE THE HIGHEST PROPORTI

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • World
  • PROPORTION OF DIARRHEA TO GASTROINTESTINAL CLINICAL TRIALS, E7 COUNTRIES (%), 2017*
  • Clinical Trials by G7 Countries: Proportion of Diarrhea to Gastrointestinal Clinical...
  • Gastrointestinal Drug
  • Opioid
  • Pharmaceutical
  • World
  • Product Initiative
  • Clinical Trial profile. 851 Trial Title

PROPORTION OF ESOPHAGEAL DISEASES TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF ESOPHAGEAL DISEASES TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* IN TOTAL THERE WERE ## CLINICAL TRIALS CONDUCTED ON ESOPHAGEAL DISEASES, AS OF AUGUST 2017

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • World

PROPORTION OF EMESIS (VOMITING) TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF EMESIS (VOMITING) TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF EMESIS (VOMITING) TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%),

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • World
  • Product Initiative
  • Clinical Trials by E7 Countries: Proportion of Constipation to Gastrointestinal Clinical...
  • PROPORTION OF CONSTIPATION TO GASTROINTESTINAL CLINICAL TRIALS, G7 COUNTRIES (%),...
  • Drug Discovery And Development
  • Gastrointestinal Drug
  • World
  • Product Initiative
  • Braintree Laboratories Inc.
  • Opioid-Induced Constipation (OIC) - Pipeline by Theravance Biopharma Inc, H2 2017
  • Opioid-Induced Constipation (OIC) - Pipeline by Sucampo Pharmaceuticals Inc, H2 2017

These medicines affect the gastrointestinal tract in a variety of ways.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Opioid
  • World
  • Product Initiative

PROPORTION OF DUODENAL ULCER TO GASTROINTESTINAL CLINICAL TRIALS, G## COUNTRIES (%), 2017* PROPORTION OF DUODENAL ULCER TO GASTROINTESTINAL CLINICAL TRIALS, G## COUNTRIES (%), 2017* In total there were ## clinical trials conducted on Duodenal Ulcer, as of July 2017 in G## Countries, o

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • World
  • Product Initiative

PROPORTION OF DYSPEPSIA TO GASTROINTESTINAL CLINICAL TRIALS, G## COUNTRIES (%), 2017* Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials are taken for a time period of 1995 - 2017 2017 trials are taken as of July 2017 PROPORTION OF DYSPEPSIA TO

  • Clinical Trial
  • Drug Discovery And Development
  • Gastrointestinal Drug
  • World
  • Yt Blood Group

PROPORTION OF BARRETTS ESOPHAGUS TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF BARRETTS ESOPHAGUS TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* AS OF APRIL 2017, THERE WERE ## CLINICAL TRIALS IN PHASE II, OF WHICH THREE CLINICAL TRIALS WE

  • Gastrointestinal Drug
  • Hospital
  • Therapy
  • World
  • Product Initiative

PROPORTION OF FUNCTIONAL (NON ULCER) DYSPEPSIA TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF FUNCTIONAL (NON ULCER) DYSPEPSIA TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF FUNCTIONAL (NON ULCER) DYSPEPSIA TO

  • Gastrointestinal Drug
  • Pharmaceutical
  • World
  • Product Initiative
  • Yt Blood Group

PROPORTION OF ACIDITY TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF ACIDITY TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF ACIDITY TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* Source: GlobalData'

  • Gastrointestinal Drug
  • Therapy
  • World
  • Product Initiative
  • Bayer AG

PROPORTION OF CORROSIVE ESOPHAGITIS (EROSIVE ESOPHAGITIS) TO GASTROINTESTINAL CLINICAL TRIALS, G## COUNTRIES (%), 2017* PROPORTION OF CORROSIVE ESOPHAGITIS (EROSIVE ESOPHAGITIS) TO GASTROINTESTINAL CLINICAL TRIALS, G## COUNTRIES (%), 2017* In total there were ## clinical trials condu

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Therapy
  • World
  • Takeda Pharmaceutical Company Limited
  • FECAL INCONTINENCE THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT...

PROPORTION OF FECAL INCONTINENCE TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF FECAL INCONTINENCE TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF FECAL INCONTINENCE TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%

  • Gastrointestinal Drug
  • Therapy
  • World
  • Product Initiative
  • RDD Pharma

Upper gastrointestinal endoscopy will be performed prior to drug treatment, and at the end of the ##-day study period.

  • Drug Discovery And Development
  • Gastrointestinal Drug
  • World
  • Product Initiative
  • AstraZeneca PLC